Inside Sanofi’s Genomic Medicine Vision with Mike Quigley, Ph.D.
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Inside Sanofi’s Genomic Medicine Vision with Mike Quigley, Ph.D.
-
Narrado por:
-
De:
We love to hear from our listeners. Send us a message.
On episode 112 of Cell & Gene: The Podcast, Michael Quigley, Ph.D., Chief Scientific Officer and Global Head of Research at Sanofi talks to Host Erin Harris about the establishment of Sanofi’s dedicated Genomic Medicine Unit (GMU). Dr. Quigley emphasizes in vivo delivery and process optimization to improve patient experience, scalability, and global access. They discuss the importance of partnerships with academia, industry, and regulators, and Dr. Quigley discusses how advances in AI are accelerating research efficiency, molecule optimization, and experimental design across Sanofi’s portfolio. He also points to the breakthroughs likely to revolutionize immunology and gene therapy, such as solutions to pre-existing immunity barriers, improved tissue-specific delivery, regulated and reversible gene therapies, and more precise gene editing.
Cell & Gene: The Podcast and Cell & Gene are part of the Life Science Connect family of resources.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn